Menu
Supporting Your Heart and Improving Your Quality of Life
In 2025, AdjuCor, in collaboration with its clinical partners, successfully completed the world’s first-in-human study of an extra-vascular heart assist device (reBEAT). In this early feasibility clinical trial, the device was evaluated for its safety and effectiveness in patients with advanced heart failure. This ongoing research builds on AdjuCor’s extensive pre-clinical testing, which has also demonstrated the long-term feasibility of the reBEAT system. AdjuCor is now in preparation for the next clinical trial phase focusing on temporary support for up to 30 days in patients requiring cardiac support while awaiting heart transplantation.
The reBEAT system is a unique, minimally invasive, epicardial, biventricular mechanical circulatory support technology designed to assist one or both ventricles of the failing heart without blood contact. This innovative approach is intended to provide support in everyday life for patients who have lost their natural heart function and are awaiting a heart transplant.
Minimizes risk for stroke and bleeding and simplifies the procedure.
Faster recovery and thus expected shorter hospital stays.
Supports one or both heart chambers, provides pulsatile support, and is individually adjustable.
Unique features aimed to help you recover quicker from implantation and regain activities you used to enjoy, thanks to reduced complications.
Shorter procedure times and subsequent lower hospitalization costs benefit both patients and healthcare institutions.